CPHI Podcast Series: The power of proteins in antibody drug development
.png)
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development.
Thomas Cornell, Senior Manager of Protein Engineering at Abzena joins the podcast to talk about the world of protein engineering, how it’s an invaluable tool for improving the stability, functionality, and applicability for drug products.
Cornell gained his PhD from Kings College London in the field of Chemical Biology. He then moved into the biotech startup space and spent almost a decade in preclinical vaccine research and development, focused on subunit vaccines. After working on over 20 protein families, Cornell has gained a wealth of protein engineering experience. Joining Abzena 2 years ago and now working within the protein engineering department on pre-clinical development of antibody drug candidates places Cornell at the heart of drug development at Abzena.
The podcast covers the field of protein engineering more broadly, and includes the parts that are particularly exciting at the minute. We explore more in depth the key aspects of antibody drugs, how these can improve patient outcomes by being more specfic and stable, and the potential for bispecifics in improving functionality. We also touched on the wider considerations of the field, such as genomics, for building a wider knowledge base that individual drug makers could utlisie better to create drugs that take into account the more individual requirements of different populations.
Finally, Cornell commented on the potential in the future for using computational design and AI to develop drugs more safely, circumventing the need for animal models, and improving time from design to market.
Listen to the full episode here >>>
Related News
-
News A Day in the Life of a Vice President of Business Development
In this month's Day in the Life Of interview, I spoke to Nigel Stapleton, VP of Business Development in Biopharmaceutical Contract Manufacturing for Mabion SA, about his illustrious career and some personal highlights. -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News China import tax fine could cost AstraZeneca up to US$8 million
British-Swedish drugmaker AstraZeneca could find itself facing fines of up to US$8million in China due to suspected unpaid import taxes on breast cancer drug Enhertu.
-
News Women in Pharma: Building from the ground up together
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pharmaceutical Packaging Market Prospects – Innovations in Packaging and Drug Delivery
Download the Pharmaceutical Packaging Market Prospects Trend Report to explore the full report and delve into the evolving opportunities in pharmaceutical packaging and drug delivery. -
News Novartis to invest US$23 billion in US facilities amid tariff threats
Swiss pharmaceutical giant Novartis has announced its intention to invest up to US$23 billion in building and expanding ten pharmaceutical facilities in the US as drugmakers scramble to respond to potential drug import and manufacturing tariffs declare... -
News CPHI Podcast Series: Fulfilling an unmet need for rare disease patients
Our April episode from the CPHI Podcast Series is looking into rare diseases, and more specifically how pharmaceutical companies can better support this smaller population of rare disease patients.